NCT01385072
Unknown
Phase 1
Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies
ConditionsRelapsed and Refractory Acute Leukemia
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Relapsed and Refractory Acute Leukemia
- Sponsor
- Rabin Medical Center
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Acute graft versus host disease rate,severity and response to treatment
- Last Updated
- 14 years ago
Overview
Brief Summary
Patients with active acute leukemia have dismal prognoses even with allogeneic transplantation.Thus,new measures to enhance graft versus leukemia effect and reduce relapse rates are needed.
Relapse risk after double umbilical cord transplantations have been shown to be significantly lower compared to matched sibling and matched unrelated donor transplantations due to better graft versus leukemia effect.
The investigators hypothesize, that concomitant transplantation from 2 matched siblings may improve GVL effect and reduce relapse rate in patients with high risk acute leukemias and other high risk hematological malignancies.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 years or older
- •Patients with refractory or relapsed acute leukemia unable to receive myeloablative conditioning.
- •Patients with refractory or relapsed acute leukemia able to receive myeloablative conditioning but with the following factors:
- •AML- 2 or more of the following: duration of CR1 \< 6 months, poor cytogenetics, circulating blasts, karnofsky \<
- •ALL- age \> 40 or second and additional relapse, or 2 or more of the following: BM blasts \> 25%, age 18-39,first refractory relapse, donor CMV positive.
- •Patients with 2 matched siblings and donor age \> 18 years old.
- •Patients with advanced multiple myeloma with life expectancy of less than 6 months with standard therapy or transplantation.
- •Patients with advanced lymphoma with life expectancy of less than 6 months with standard therapy or transplantation.
Exclusion Criteria
- •Patient age \< 18 years.
- •Donor age \< 18 years.
- •Patients in remission or not fulfilling above disease criteria -
Outcomes
Primary Outcomes
Acute graft versus host disease rate,severity and response to treatment
Time Frame: 100 days
Secondary Outcomes
- relapse rate(12 months)
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)Hematological MalignanciesNCT01139164Medical University of South Carolina78
Completed
Phase 2
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous LeukemiaAcute Myelogenous LeukemiaNCT00623935University of Michigan Rogel Cancer Center56
Terminated
Not Applicable
Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected PatientsHIV-1 InfectionNCT02732457Kirby Institute5
Not yet recruiting
Not Applicable
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid LeukemiaAMLNCT06643195Institute of Hematology & Blood Diseases Hospital, China358
Not yet recruiting
Phase 2
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft FailureHematologic DiseasesGraft FailureAllogeneic Hematopoietic Stem Cell TransplantationNCT05126186Assistance Publique - Hôpitaux de Paris35